These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 11364903

  • 1. HIV research overview: interview with David Ho, M.D. Interview by John S. James.
    Ho D.
    AIDS Treat News; 1997 Nov 07; (No 282):1-6. PubMed ID: 11364903
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. How far can you knock down HIV? An interview with David D. Ho, MD. Interview by Mark Mascolini.
    Ho DD.
    J Int Assoc Physicians AIDS Care; 1997 Jun 07; 3(6):40-4. PubMed ID: 11364429
    [Abstract] [Full Text] [Related]

  • 4. In search of the Holy Grail: Martin Markowitz, M.D., on the dream of eradication.
    Markowitz M.
    Res Initiat Treat Action; 1998 Apr 07; 4(2):9-13. PubMed ID: 11365230
    [Abstract] [Full Text] [Related]

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Apr 07; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical implications of virological "failure": interview with Steven Deeks, M.D., San Francisco General Hospital. Interview by John S. James.
    Deeks S.
    AIDS Treat News; 1998 Feb 20; (No 289):1-6. PubMed ID: 11365047
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 20; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 10. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan 20; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
    Conant M.
    AIDS Treat News; 1995 Aug 04; (no 228):1-3. PubMed ID: 11362623
    [Abstract] [Full Text] [Related]

  • 16. New antiretroviral tactics: transitions or mere trends? An interview with Joep Lange,MD,PhD. Interview by Mark Mascolini.
    Mascolini M.
    J Int Assoc Physicians AIDS Care; 1999 Jul 04; 5(7):25-9. PubMed ID: 11367133
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.
    Antivir Ther; 2008 Jul 04; 13(7):927-36. PubMed ID: 19043927
    [Abstract] [Full Text] [Related]

  • 20. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveira RH, Sill AM, DeVico A, Tanuri A.
    J Clin Virol; 2004 May 04; 30(1):24-31. PubMed ID: 15072750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.